Gregory Krauss, MD
Neurology · Baltimore, MDNPI 1114964921
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $31,240 of the $45,474 with a category attached, or 68.7%. 8 manufacturers reported payments, led by SK Life Science, Inc. at 41.6% of the total. Reporting peaked in 2019 at $18,439 and has fallen 80.8% since, to $3,543 in 2025. Among neurology clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 61 payments — averaging $745.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- SK Life Science, Inc.$19K
- Eisai Inc.$15K
- UCB, Inc.$11K
- Merck$850
- Neurelis, Inc.$183
- Catalyst Pharmaceuticals, Inc.$67
- plus $37 from 2 others
Across 110 payments — averaging $8660.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- SK Life Science, Inc.$584K
- UCB SA$272K
- Eisai Inc.$68K
- AbbVie$24K
- Biogen$5K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$400
What the payments were for
- Consulting fees$31,24069%
- Speaking & faculty fees$10,95024%
- Travel & lodging$1,3703%
- Food & beverage$1,9144%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| SK Life Science, Inc. | 21 | $18,896 |
| Eisai Inc. | 4 | $14,516 |
| UCB, Inc. | 26 | $10,926 |
| Merck | 2 | $850 |
| Neurelis, Inc. | 4 | $183 |
| Catalyst Pharmaceuticals, Inc. | 2 | $67 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Livanova USA, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$45,474 in reported general payments places this provider in the 90th percentile of 442 neurology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XcopriCenobamate | 212 | $494,752 |
| Vigabatrin | 32 | $487,677 |
| FinteplaFenfluramine Hcl | 14 | $269,941 |
| BriviactBrivaracetam | 103 | $254,907 |
| Rufinamide | 43 | $84,258 |
| AptiomEslicarbazepine Acetate | 25 | $74,511 |
| Lacosamide | 194 | $47,837 |
| Clobazam | 99 | $15,060 |
| VimpatLacosamide | 13 | $13,670 |
| KeppraLevetiracetam | 12 | $12,574 |
| ValtocoDiazepam | 14 | $11,017 |
| Levetiracetam | 173 | $8,994 |
| DilantinPhenytoin Sodium Extended | 16 | $4,929 |
| Divalproex Sodium | 37 | $3,734 |
| Divalproex Sodium ErDivalproex Sodium | 36 | $2,977 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Fintepla, Briviact, Vimpat | $10,926 | $538,518130 claims |
| SK Life Science, Inc.Xcopri | $18,896 | $494,752212 claims |
| Neurelis, Inc.Valtoco | $183 | $11,01714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 442 neurology providers in Maryland.
Other neurology in Baltimore
- Michael PolydefkisBaltimore$371K
- Shiv SaidhaBaltimore$298K
- Santiago Mazuera MesiaBaltimore$258K
- Thomas CrawfordBaltimore$215K
- Scott NewsomeBaltimore$203K
- Perry ForemanBaltimore$194K
- Samuel MillerBaltimore$179K
- Ted DawsonBaltimore$170K
- Charlene GamaldoBaltimore$131K
- Kathryn WagnerBaltimore$120K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.